Absolute count of T and B lymphocyte subsets is decreased in systemic sclerosis. 2010

Thilo Gambichler, and C Tigges, and B Burkert, and S Höxtermann, and P Altmeyer, and A Kreuter
Department of Dermatology, Ruhr-University Bochum, 44791 Bochum, Germany. t.gambichler@klinikum-bochum.de

BACKGROUND Previous reports on lymphocyte subpopulations in systemic sclerosis (SSc) are conflicting. Therefore, we aimed to investigate the lymphocyte subsets in SSc patients who were not on immunosuppressive therapy. METHODS Lymphocyte subsets were assessed in the peripheral blood of SSc patients (n = 29) and healthy controls (n = 29) using the four colour flow cytometry method. Correlation studies were also performed in order to assess the relationship between lymphocyte subsets and clinical parameters. RESULTS The absolute count of lymphocytes (P = 0.0042), CD3+ (P = 0.0014), CD4+ (P = 0.0070), CD8+ (P = 0.021), and CD19+ cells (P = 0.024) was significantly decreased in SSc patients when compared to healthy controls. CD4+/CD8+ ratio and the absolute count of CD56+ cells observed in SSc patients did not significantly differ from controls (P=0.165; P = 0.632, respectively). There was no substantial relationship between the lymphocyte subset levels and clinical features (i.e., SSc subtype, autoantibody profiles, organ involvement), except for a significant inverse correlation of CD19+ cells and the modified Rodnan skin score (r = -0.43, P = 0.020). CONCLUSIONS Our data support previous reports indicating that subsets of T lymphocytes as well as B lymphocytes play a role in the pathogenesis of SSc.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011928 Raynaud Disease An idiopathic vascular disorder characterized by bilateral Raynaud phenomenon, the abrupt onset of digital paleness or CYANOSIS in response to cold exposure or stress. Cold Fingers, Hereditary,Raynaud Phenomenon,Raynaud's Disease,Raynauds Disease
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012595 Scleroderma, Systemic A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA. Sclerosis, Systemic,Systemic Scleroderma,Systemic Sclerosis
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity
D016175 B-Lymphocyte Subsets A classification of B-lymphocytes based on structurally or functionally different populations of cells. B-Cell Subsets,Tumor-Infiltrating B Cells,Tumor-Infiltrating B Lymphocytes,B Effector 1 Cells,B Effector 2 Cells,B-1 Cells,B-1 Lymphocytes,B-2 Lymphocytes,B-Lymphocytes, Effector,B1 Lymphocytes,B2 Lymphocytes,Be1 Cells,Be2 Cells,Effector B Cells,B 1 Cells,B 1 Lymphocytes,B 2 Lymphocytes,B Cell Subsets,B Cell, Tumor-Infiltrating,B Lymphocyte Subsets,B Lymphocyte, Tumor-Infiltrating,B-1 Cell,B-1 Lymphocyte,B-2 Lymphocyte,B-Cell Subset,B-Lymphocyte Subset,B-Lymphocyte, Effector,B1 Lymphocyte,B2 Lymphocyte,Be1 Cell,Be2 Cell,Cell, B-1,Cell, Be1,Cell, Be2,Effector B Cell,Effector B-Lymphocyte,Effector B-Lymphocytes,Lymphocyte, B-1,Lymphocyte, B-2,Lymphocyte, B1,Lymphocyte, B2,Tumor Infiltrating B Cells,Tumor Infiltrating B Lymphocytes,Tumor-Infiltrating B Cell,Tumor-Infiltrating B Lymphocyte

Related Publications

Thilo Gambichler, and C Tigges, and B Burkert, and S Höxtermann, and P Altmeyer, and A Kreuter
January 2010, Prague medical report,
Thilo Gambichler, and C Tigges, and B Burkert, and S Höxtermann, and P Altmeyer, and A Kreuter
March 2014, European journal of internal medicine,
Thilo Gambichler, and C Tigges, and B Burkert, and S Höxtermann, and P Altmeyer, and A Kreuter
January 1985, Bollettino dell'Istituto sieroterapico milanese,
Thilo Gambichler, and C Tigges, and B Burkert, and S Höxtermann, and P Altmeyer, and A Kreuter
September 2020, Clinical lymphoma, myeloma & leukemia,
Thilo Gambichler, and C Tigges, and B Burkert, and S Höxtermann, and P Altmeyer, and A Kreuter
February 1981, The Journal of laboratory and clinical medicine,
Thilo Gambichler, and C Tigges, and B Burkert, and S Höxtermann, and P Altmeyer, and A Kreuter
January 2022, Frontiers in pharmacology,
Thilo Gambichler, and C Tigges, and B Burkert, and S Höxtermann, and P Altmeyer, and A Kreuter
May 2018, Multiple sclerosis (Houndmills, Basingstoke, England),
Thilo Gambichler, and C Tigges, and B Burkert, and S Höxtermann, and P Altmeyer, and A Kreuter
April 1987, Immunitat und Infektion,
Thilo Gambichler, and C Tigges, and B Burkert, and S Höxtermann, and P Altmeyer, and A Kreuter
April 2008, British journal of haematology,
Thilo Gambichler, and C Tigges, and B Burkert, and S Höxtermann, and P Altmeyer, and A Kreuter
April 2024, International journal of rheumatic diseases,
Copied contents to your clipboard!